Short and medium‐term efficacy of sodium glucose co‐transporter‐2 (SGLT‐2) inhibitors: A meta‐analysis of randomized clinical trials

Monami, Matteo; Liïstro, Francesco; Scatena, Alessia; Nreu, Besmir; Mannucci, Edoardo

doi:10.1111/dom.13221

Cited by 43 publications

(35 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consistent with the β‐cell–independent mechanism of action of dapagliflozin, lower CoF was observed with dapagliflozin than with saxagliptin where efficacy may be limited by reduced β‐cell capacity, especially in patients with higher HbA1c . The greater durability of HbA1c control with dapagliflozin versus saxagliptin over 20–102 weeks is consistent with a recent meta‐analysis that showed that SGLT2 inhibitors achieved greater efficacy for glycaemic control than DPP4 inhibitors up to 52 weeks . Long‐term dapagliflozin treatment in patients with T2DM has achieved glucose‐lowering efficacy and associated reductions in blood pressure and body weight across a broad spectrum of patients, including those with cardiovascular and renal comorbidities .…”

Section: Discussionsupporting

confidence: 79%

“…[9][10][11] The greater durability of HbA1c control with dapagliflozin versus saxagliptin over 20-102 weeks is consistent with a recent meta-analysis that showed that SGLT2 inhibitors achieved greater efficacy for glycaemic control than DPP4 inhibitors up to 52 weeks. 12 Long-term dapagliflozin treatment in patients with T2DM has achieved glucose-lowering efficacy and associated reductions in blood pressure and body weight across a broad spectrum of patients, including those with cardiovascular and renal comorbidities. 13 Thus, our findings support the long-term efficacy and safety profile of dapagliflozin previously reported, as monotherapy or as an adjunct to metformin in patients with inadequately controlled T2DM.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Bailey

Prato

Wei

et al. 2019

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Dapagliflozin is associated with greater reductions in HbA1c and weight than saxagliptin in management of type 2 diabetes mellitus (T2DM). The present post hoc analyses compared the durability of these effects over short‐ and long‐term follow‐up in patients with T2DM who were inadequately controlled with metformin (≥1500 mg/day) and who were receiving either dapagliflozin (10 mg/day) or saxagliptin (5 mg/day). Failure of glycaemiccontrol was assessed using the slope of the change in HbA1c from baseline‐over‐time regression line (coefficient of failure [CoF]). CoF was compared directly (dapagliflozin vs saxagliptin) over the short term (NCT01606007, 24 weeks) and indirectly (placebo‐adjusted) over the long term (NCT00528879 and NCT00121667, 102 weeks). A low CoF value indicated greater durability. CoF was lower for dapagliflozin versus saxagliptin over 18–24 weeks (−1.38%/year; 95% CI, −2.41 to −0.35; P = .009) and 20–102 weeks (−0.37%/year; 95% CI, −0.73 to −0.02; P = .04). Fewer dapagliflozin‐treated patients versus saxagliptin‐treated patients required rescue medication or discontinued the study because of failure to achieve glycaemic control at 24 weeks (3.4% vs 9.4%; P = .0191). In patients with T2DM who were inadequately controlled with metformin, dapagliflozin was associated with greater durability of glycaemic control than saxagliptin over 18–24 and 20–102 weeks.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Bailey

Prato

Wei

et al. 2019

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…Results showed that compared to DPP4i, SGLT2i had a better persistence of efficacy, at least up to 2 years. Sulfonylureas were more effective in the short term but less effective in the longer term when compared to SGLT2i [41].…”

Section: Durabilitymentioning

confidence: 89%

Management of Type 2 Diabetes in Developing Countries: Balancing Optimal Glycaemic Control and Outcomes with Affordability and Accessibility to Treatment

et al. 2019

View full text Add to dashboard Cite

Why carry out this study? Diabetes mellitus is becoming a global epidemic but it disproportionally affects poorer developing countries. Newer agents, although increasingly recognized by some international guidelines, are not always widely accessible and affordable, unlike long-standing drugs such as sulfonylureas (SUs) This review considers existing antidiabetic drugs and makes a case for appropriateness of SUs, especially newer generation SUs What was learned from the study? The newer drugs like DPP4 inhibitors, SGLT2 inhibitors and GLP-1 receptor agonists, while showing benefits, may not be affordable and accessible for many individuals in developing countries The newer generation SUs like gliclazide and glimepiride are time-tested, effective, safe and should continue to be used especially in resource-restricted settings

show abstract

“…SGLT-2 inhibitors (canagliflozin, dapagliflozin, empagliflozine, ertugliflozin) are effective antihyperglycaemic substances in the treatment of type 2 diabetes in both mono-and combination therapy with all other glucose-lowering drugs. Their efficacy profile is favourable, also because the risk of hypoglycaemia is low, patients lose weight and there is a clinically relevant reduction in systolic blood pressure [70][71][72][73][74][75][76][77]. They also significantly reduce cardiovascular and renal endpoints (see below).…”

Section: Sglt-2 Inhibitorsmentioning

confidence: 99%

Therapy of Type 2 Diabetes

Landgraf

Aberle

Birkenfeld

et al. 2019

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

The practical recommendations of the German Diabetes Society/ Deutsche Diabetes Gesellschaft (DDG) together with the German Society for Internal Medicine/Deutschen Gesellschaft für Innere Medizin (DGIM) are based on the contents of the National Treatment Guideline (Nationale Versorgungsleitlinie NVL) "Therapy of Type 2 Diabetes" [1]. The modifications in therapy and their justifications made in the present DDG practical recommendations were updated on the basis of new randomized controlled trials (RCTs) and meta-analyses and were consented by the DDG and the DGIM. Definition of Type 2 DiabetesType 2 diabetes is a chronic, very heterogeneous, multi-factorial, progressive disease characterized by inherited and acquired insulin resistance and qualitative and quantitative insulin secretion disturbances.Influenceable and uninfluenceable risk factors for type 2 diabetes are listed in the "Risk factors for type 2 diabetes" infobox. Therapeutic goalsIn the present recommendations, target ranges are identified which -with varying levels of strengths of evidence -inform the physician and the patient on which target range/target value should be aimed for according to current medical knowledge based on evidence and consensus. The main objective remains to set individual therapy goals primarily together with the patient and possibly his or her relatives and agreeing them optimally in writing on a quarterly basis (e. g. in the Health Passport Diabetes). General and specific therapeutic goalsThe therapeutic goals of people with type 2 diabetes depend on patient preference, comorbidity, duration of the disease, age and life expectancy, quality of life, cultural conditions, psychosocial circumstances and possibilities as well as abilities of the persons S73This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.

show abstract

Short and medium‐term efficacy of sodium glucose co‐transporter‐2 (SGLT‐2) inhibitors: A meta‐analysis of randomized clinical trials

Abstract: SGLT-2 inhibitors showed a good persistence of efficacy, at least up to 2 years, with a small but significant superiority over DPP-4i. Sulfonylureas are more effective in the very short term, but less effective in the longer term.

Cited by 43 publications

References 40 publications

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Management of Type 2 Diabetes in Developing Countries: Balancing Optimal Glycaemic Control and Outcomes with Affordability and Accessibility to Treatment

Therapy of Type 2 Diabetes

Contact Info

Product

Resources

About